When Marijuana is Legal, Teens See Cannabis Ads

LabRoots | November 25, 2019

Despite federal policies in place to restrict marijuana marketing to individuals under 21 years old, an overwhelming majority of teenagers are still exposed to such campaigns, a new study shows. The survey’s results suggest that restrictive policies need to tighten up in order to reduce the exposure of marijuana marketing to vulnerable populations. Researchers recently conducted an online survey of 469 teenagers between the ages of 15 and 19 in four states where recreational marijuana is legal: California, Colorado, Nevada, and Washington. They asked the participants about their social media use, marijuana use, and exposure to marijuana marketing. Almost all (94%) of survey respondents reported seeing marijuana marketing in some shape or form. Not surprisingly, teens who completed the survey were more likely to have been exposed to marijuana marketing via social media than via billboards. However, exposure to both was high; 73% saw marijuana advertisements on billboards and 79% on social media, specifically Facebook, Twitter, and Instagram. While apparently not very effective, restrictions do exist on paid advertising for cannabis on social media. Recreational marijuana may be legal in certain states under state law, but the drug is still illegal on a federal level. Federal regulations prevent cannabis companies from running marijuana marketing campaigns regardless of the state’s specific policies on the use of the drug.

Spotlight

The bulk physical properties such as strength and toughness of materials such as synthetic and natural polymers, or the activity and efficacy of proteins and biopharmaceuticals are strongly dependent on their molecular properties.

Spotlight

The bulk physical properties such as strength and toughness of materials such as synthetic and natural polymers, or the activity and efficacy of proteins and biopharmaceuticals are strongly dependent on their molecular properties.

Related News

RESEARCH

IDBS Launches Polar™ in a New Product Category That Aims to Streamline and Speed up Biopharmaceutical Development

IDBS | December 07, 2020

IDBS, a product informatics arrangement supplier for biotech and pharma, today reported the dispatch of Polar™, building up another item classification, BioPharma Lifecycle Management (BPLM), pointed toward smoothing out medication advancement and assembling in biopharma research. The advancement of biologics is a unique cycle and the individuals who are best should have the option to adjust to changes in cycle or innovation quickly. IDBS information has discovered that without compelling BPLM, the advancement of a biologic can take as long as three years longer than it should, which impacts the two patients and an organization's primary concern. Despite the fact that biopharma organizations perceive the requirement for proficiency, quality and information honesty, most are as yet losing time to paper records, Excel and other specially appointed frameworks that defer results and endanger measure understanding and quality. Without more productive frameworks, organizations will keep on creating irreproducible outcomes, which prompts rehashed work, inability to separate experiences and postpones development. "Putting up a medication for sale to the public is an unpredictable cycle which proceeds with post-commercialization," said Umay Saplakoglu, Chief Digital Officer at Cytiva. "A significant test today is that information that is created all through the periods of disclosure doesn't generally get moved and rather exists in storehouses – in hardware, in somebody's scratch pad or in an information base. There are no communitarian stages where you can dissect the information and draw experiences from it. This remaining parts probably the greatest test confronting industry today." Polar™ is intended to be quickly sent to explain work process, measure quality, joint effort and information investigation challenges that have pained presently accessible programming arrangements including LIMS and ELN. It will decrease manual information preparing and record, prompting less human mistakes and improved generally speaking precision, and incorporates complete pursuit capacities that help clients find what they are searching for, diminishing the need to pointlessly copy measures. Besides, by making a profoundly contextualized information spine that underpins the entire improvement lifecycle, Polar™ offers out-of-the-crate understanding and investigation, assisting organizations with understanding the advantages of demonstrating and reproduction, helping drive development and decrease time-to-showcase. Polar™, will empower organizations to all the more viably explore the complexities and failures of the medication advancement lifecycle, while receiving the groundbreaking rewards that come from a well curated cycle and quality information spine.

Read More

Moberg Pharma decides on fully guaranteed rights issue of approximately SEK 150 million

Moberg Pharma | November 06, 2020

The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) ("Moberg Pharma" or "the Company") has today resolved to carry out a fully guaranteed issue of new ordinary shares and warrants ("Units") with preferential rights for existing shareholders (the "Rights Issue") of approximately SEK 150 million before transaction costs. The Rights Issue requires the approval of an extraordinary general meeting (the "Extraordinary General Meeting"). The proceeds will be used for registration activities and clinical work for MOB-015. When the Rights Issue is completed, the Company intends to terminate the current convertible note agreement. By a separate press release, the Company has today announced its intention to distribute the BUPI project to the shareholders of Moberg Pharma through a Lex Asea distribution with a subsequent listing on Nasdaq First North Growth Market during the Q1 of 2021.

Read More

Aphria, ODI Pharma execute supply agreement

ODI Pharma | November 03, 2020

ODI Pharma AB today announced that, despite COVID 19 delays, it has streamlined its supply chain and executed a Supply Agreement (the "Supply Agreement") with Aphria Inc.'s ("Aphria") (TSX: APHA) (Nasdaq: APHA) wholly-owned German subsidiary, CC Pharma GmbH ("CC Pharma"). The management team of ODI believes the Supply Agreement will contribute to efficiencies of ODI's operations going forward. The highlights of the Supply Agreement are: The Supply Agreement grants ODI the exclusive right to sell a defined set of co-branded products in Poland. These products will be co-branded and sold under the ODI and Aphria brand names; The Supply Agreement has a term of five years and provides for an annual minimum of 1,200 kg of medical cannabis product, for a total of 6,000 kg of medical cannabis during the term of the agreement; and CC Pharma will support ODI in securing regulatory approval for import and sale of the co-branded products in Poland. Aphria Inc. Chief Executive Officer and Chairman, Irwin D. Simon comments "We are pleased to announce our partnership with ODI Pharma, which expands the international presence of our Aphria medical brand into Poland. This partnership is further evidence of our global commitment to provide patients with access to high-quality medical cannabis products as well as a testament to the strength and quality of our medical brand, Aphria. We look forward to working with ODI Pharma in bringing our high-quality medical cannabis products to patients in Poland." ODI Pharma AB CEO Derek Simmross comments "We are pleased to continue our relationship with Aphria through our new partnership between CC Pharma and ODI Pharma. We see that this will contribute to our operational efficiency and it is exciting to further advance the terms of our relationship to include a broader product offering. Our goal remains to represent the best and most technologically advanced producer of medical cannabis in the industry for the Polish people." ODI Pharma AB Chairman Volker Wiederrich comments "We are proud of our partnership with CC pharma, a global leader who shares with us the same quality values and commitments of meeting patients' needs and improving their quality of life. Also, this is another vote of confidence in ODI Pharma's leadership and the Polish medical cannabis market." About ODI Pharma AB ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. ODI will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals. About Aphria Inc. Aphria Inc. is a leading global cannabis company inspiring and empowering the worldwide community to live their very best life. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria Inc. has been setting the standard for the low-cost production of high-quality cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria Inc. is committed to bringing breakthrough innovation to the global cannabis market. Aphria's portfolio of brands is grounded in expertly researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders' multi-generational expertise in commercial agriculture, Aphria Inc. drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion.

Read More